Guillain-Barre’-like Syndrome after Nelarabine Treatment
Although current treatment can improve the complete remission rate of T-cell acute lymphoblastic leukemia (T-ALL), approximately half of the patients relapse within the first 2 years and have poor prognosis. Nelarabine is a novel purine nucleoside analog, and has been proven efficacious against both...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wolters Kluwer Medknow Publications
2014-09-01
|
| Series: | Journal of Cancer Research and Practice |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2311300616300349 |